Cervical cancer screening and associated treatment costs in France

Oncogenic human papillomaviruses (HPV) cause cervical cancer (CC). Screening prevents CC by detecting and removing cervical intraepithelial neoplasia (CIN) lesions that are detected through abnormal Pap smears. This study assessed the costs of CC screening, management of abnormal Pap smears, and tre...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gynécologie, obstétrique & fertilité obstétrique & fertilité, 2006-11, Vol.34 (11), p.1036-1042
Hauptverfasser: Bergeron, C, Breugelmans, J-G, Bouée, S, Lorans, C, Bénard, S, Rémy, V
Format: Artikel
Sprache:fre
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1042
container_issue 11
container_start_page 1036
container_title Gynécologie, obstétrique & fertilité
container_volume 34
creator Bergeron, C
Breugelmans, J-G
Bouée, S
Lorans, C
Bénard, S
Rémy, V
description Oncogenic human papillomaviruses (HPV) cause cervical cancer (CC). Screening prevents CC by detecting and removing cervical intraepithelial neoplasia (CIN) lesions that are detected through abnormal Pap smears. This study assessed the costs of CC screening, management of abnormal Pap smears, and treatment of CIN in France. Pap smears received by laboratory Pasteur-Cerba during a 7-month period were examined. Patients with abnormal Pap smears were identified and followed for 6 months after diagnosis. The management of abnormal Pap smears was documented. These data and other published studies were used to estimate the total number of pap smears, distribution of abnormal smears requiring further examinations, and number of CIN diagnosed. Economic analyses were performed to estimate total CC screening costs from the health care payer (HCP) and societal perspective. An estimated 6,111,787 Pap smears were performed in 2004, including 222,350 abnormal (3.9%) and 63,616 follow-up smears. In total, 58,920 cervical biopsies and 52,525 HPV tests were performed after an abnormal Pap smear. The cost associated with CC screening, including management of abnormal findings, was estimated at 174.2 million euro from the HCP perspective. Total treatment cost for all CIN was estimated at 22.3 million euro (HCP perspective). Overall cost for screening, diagnosis and management of Pap smears was estimated at 335.7 million euro of which 196.5 million euro where funded by the HCP. An HPV vaccine that prevents pre-cancerous or cancerous lesions of the cervix will decrease the socio-economic burden associated with the screening of these lesions.
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_68209912</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68209912</sourcerecordid><originalsourceid>FETCH-LOGICAL-p545-f7982a198040c0da236a8632dd72b31002bf7ebca000be448feb8351a4d1e9183</originalsourceid><addsrcrecordid>eNo1jz1PwzAURT2AaCn8BeSJLZI_ktgeIaKAVImle_RsvyCjxAm2g8S_p4gy3eXco3svyJYLoyrTaLMh1zl_MMZaI_UV2XDFFGO62ZLHDtNXcDBSB9FhotklxBjiO4XoKeQ8uwAFPS0JoUwYC3VzLpmGSPfpt3NDLgcYM96ec0eO-6dj91Id3p5fu4dDtTR1Uw3KaAHcaFYzxzwI2YJupfBeCSs5Y8IOCq2D00qLda0HtFo2HGrP0XAtd-T-T7uk-XPFXPopZIfjCBHnNfetFswYLk7g3Rlc7YS-X1KYIH33_6flD99NUZo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68209912</pqid></control><display><type>article</type><title>Cervical cancer screening and associated treatment costs in France</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Bergeron, C ; Breugelmans, J-G ; Bouée, S ; Lorans, C ; Bénard, S ; Rémy, V</creator><creatorcontrib>Bergeron, C ; Breugelmans, J-G ; Bouée, S ; Lorans, C ; Bénard, S ; Rémy, V</creatorcontrib><description>Oncogenic human papillomaviruses (HPV) cause cervical cancer (CC). Screening prevents CC by detecting and removing cervical intraepithelial neoplasia (CIN) lesions that are detected through abnormal Pap smears. This study assessed the costs of CC screening, management of abnormal Pap smears, and treatment of CIN in France. Pap smears received by laboratory Pasteur-Cerba during a 7-month period were examined. Patients with abnormal Pap smears were identified and followed for 6 months after diagnosis. The management of abnormal Pap smears was documented. These data and other published studies were used to estimate the total number of pap smears, distribution of abnormal smears requiring further examinations, and number of CIN diagnosed. Economic analyses were performed to estimate total CC screening costs from the health care payer (HCP) and societal perspective. An estimated 6,111,787 Pap smears were performed in 2004, including 222,350 abnormal (3.9%) and 63,616 follow-up smears. In total, 58,920 cervical biopsies and 52,525 HPV tests were performed after an abnormal Pap smear. The cost associated with CC screening, including management of abnormal findings, was estimated at 174.2 million euro from the HCP perspective. Total treatment cost for all CIN was estimated at 22.3 million euro (HCP perspective). Overall cost for screening, diagnosis and management of Pap smears was estimated at 335.7 million euro of which 196.5 million euro where funded by the HCP. An HPV vaccine that prevents pre-cancerous or cancerous lesions of the cervix will decrease the socio-economic burden associated with the screening of these lesions.</description><identifier>ISSN: 1297-9589</identifier><identifier>PMID: 17070085</identifier><language>fre</language><publisher>France</publisher><subject>Cost-Benefit Analysis ; Female ; France ; Health Care Costs ; Humans ; Mass Screening - economics ; Papanicolaou Test ; Papillomavirus Vaccines - economics ; Uterine Cervical Neoplasms - diagnosis ; Uterine Cervical Neoplasms - pathology ; Uterine Cervical Neoplasms - prevention &amp; control ; Vaginal Smears - economics</subject><ispartof>Gynécologie, obstétrique &amp; fertilité, 2006-11, Vol.34 (11), p.1036-1042</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17070085$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bergeron, C</creatorcontrib><creatorcontrib>Breugelmans, J-G</creatorcontrib><creatorcontrib>Bouée, S</creatorcontrib><creatorcontrib>Lorans, C</creatorcontrib><creatorcontrib>Bénard, S</creatorcontrib><creatorcontrib>Rémy, V</creatorcontrib><title>Cervical cancer screening and associated treatment costs in France</title><title>Gynécologie, obstétrique &amp; fertilité</title><addtitle>Gynecol Obstet Fertil</addtitle><description>Oncogenic human papillomaviruses (HPV) cause cervical cancer (CC). Screening prevents CC by detecting and removing cervical intraepithelial neoplasia (CIN) lesions that are detected through abnormal Pap smears. This study assessed the costs of CC screening, management of abnormal Pap smears, and treatment of CIN in France. Pap smears received by laboratory Pasteur-Cerba during a 7-month period were examined. Patients with abnormal Pap smears were identified and followed for 6 months after diagnosis. The management of abnormal Pap smears was documented. These data and other published studies were used to estimate the total number of pap smears, distribution of abnormal smears requiring further examinations, and number of CIN diagnosed. Economic analyses were performed to estimate total CC screening costs from the health care payer (HCP) and societal perspective. An estimated 6,111,787 Pap smears were performed in 2004, including 222,350 abnormal (3.9%) and 63,616 follow-up smears. In total, 58,920 cervical biopsies and 52,525 HPV tests were performed after an abnormal Pap smear. The cost associated with CC screening, including management of abnormal findings, was estimated at 174.2 million euro from the HCP perspective. Total treatment cost for all CIN was estimated at 22.3 million euro (HCP perspective). Overall cost for screening, diagnosis and management of Pap smears was estimated at 335.7 million euro of which 196.5 million euro where funded by the HCP. An HPV vaccine that prevents pre-cancerous or cancerous lesions of the cervix will decrease the socio-economic burden associated with the screening of these lesions.</description><subject>Cost-Benefit Analysis</subject><subject>Female</subject><subject>France</subject><subject>Health Care Costs</subject><subject>Humans</subject><subject>Mass Screening - economics</subject><subject>Papanicolaou Test</subject><subject>Papillomavirus Vaccines - economics</subject><subject>Uterine Cervical Neoplasms - diagnosis</subject><subject>Uterine Cervical Neoplasms - pathology</subject><subject>Uterine Cervical Neoplasms - prevention &amp; control</subject><subject>Vaginal Smears - economics</subject><issn>1297-9589</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1jz1PwzAURT2AaCn8BeSJLZI_ktgeIaKAVImle_RsvyCjxAm2g8S_p4gy3eXco3svyJYLoyrTaLMh1zl_MMZaI_UV2XDFFGO62ZLHDtNXcDBSB9FhotklxBjiO4XoKeQ8uwAFPS0JoUwYC3VzLpmGSPfpt3NDLgcYM96ec0eO-6dj91Id3p5fu4dDtTR1Uw3KaAHcaFYzxzwI2YJupfBeCSs5Y8IOCq2D00qLda0HtFo2HGrP0XAtd-T-T7uk-XPFXPopZIfjCBHnNfetFswYLk7g3Rlc7YS-X1KYIH33_6flD99NUZo</recordid><startdate>200611</startdate><enddate>200611</enddate><creator>Bergeron, C</creator><creator>Breugelmans, J-G</creator><creator>Bouée, S</creator><creator>Lorans, C</creator><creator>Bénard, S</creator><creator>Rémy, V</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200611</creationdate><title>Cervical cancer screening and associated treatment costs in France</title><author>Bergeron, C ; Breugelmans, J-G ; Bouée, S ; Lorans, C ; Bénard, S ; Rémy, V</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p545-f7982a198040c0da236a8632dd72b31002bf7ebca000be448feb8351a4d1e9183</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>fre</language><creationdate>2006</creationdate><topic>Cost-Benefit Analysis</topic><topic>Female</topic><topic>France</topic><topic>Health Care Costs</topic><topic>Humans</topic><topic>Mass Screening - economics</topic><topic>Papanicolaou Test</topic><topic>Papillomavirus Vaccines - economics</topic><topic>Uterine Cervical Neoplasms - diagnosis</topic><topic>Uterine Cervical Neoplasms - pathology</topic><topic>Uterine Cervical Neoplasms - prevention &amp; control</topic><topic>Vaginal Smears - economics</topic><toplevel>online_resources</toplevel><creatorcontrib>Bergeron, C</creatorcontrib><creatorcontrib>Breugelmans, J-G</creatorcontrib><creatorcontrib>Bouée, S</creatorcontrib><creatorcontrib>Lorans, C</creatorcontrib><creatorcontrib>Bénard, S</creatorcontrib><creatorcontrib>Rémy, V</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Gynécologie, obstétrique &amp; fertilité</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bergeron, C</au><au>Breugelmans, J-G</au><au>Bouée, S</au><au>Lorans, C</au><au>Bénard, S</au><au>Rémy, V</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cervical cancer screening and associated treatment costs in France</atitle><jtitle>Gynécologie, obstétrique &amp; fertilité</jtitle><addtitle>Gynecol Obstet Fertil</addtitle><date>2006-11</date><risdate>2006</risdate><volume>34</volume><issue>11</issue><spage>1036</spage><epage>1042</epage><pages>1036-1042</pages><issn>1297-9589</issn><abstract>Oncogenic human papillomaviruses (HPV) cause cervical cancer (CC). Screening prevents CC by detecting and removing cervical intraepithelial neoplasia (CIN) lesions that are detected through abnormal Pap smears. This study assessed the costs of CC screening, management of abnormal Pap smears, and treatment of CIN in France. Pap smears received by laboratory Pasteur-Cerba during a 7-month period were examined. Patients with abnormal Pap smears were identified and followed for 6 months after diagnosis. The management of abnormal Pap smears was documented. These data and other published studies were used to estimate the total number of pap smears, distribution of abnormal smears requiring further examinations, and number of CIN diagnosed. Economic analyses were performed to estimate total CC screening costs from the health care payer (HCP) and societal perspective. An estimated 6,111,787 Pap smears were performed in 2004, including 222,350 abnormal (3.9%) and 63,616 follow-up smears. In total, 58,920 cervical biopsies and 52,525 HPV tests were performed after an abnormal Pap smear. The cost associated with CC screening, including management of abnormal findings, was estimated at 174.2 million euro from the HCP perspective. Total treatment cost for all CIN was estimated at 22.3 million euro (HCP perspective). Overall cost for screening, diagnosis and management of Pap smears was estimated at 335.7 million euro of which 196.5 million euro where funded by the HCP. An HPV vaccine that prevents pre-cancerous or cancerous lesions of the cervix will decrease the socio-economic burden associated with the screening of these lesions.</abstract><cop>France</cop><pmid>17070085</pmid><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1297-9589
ispartof Gynécologie, obstétrique & fertilité, 2006-11, Vol.34 (11), p.1036-1042
issn 1297-9589
language fre
recordid cdi_proquest_miscellaneous_68209912
source MEDLINE; Elsevier ScienceDirect Journals
subjects Cost-Benefit Analysis
Female
France
Health Care Costs
Humans
Mass Screening - economics
Papanicolaou Test
Papillomavirus Vaccines - economics
Uterine Cervical Neoplasms - diagnosis
Uterine Cervical Neoplasms - pathology
Uterine Cervical Neoplasms - prevention & control
Vaginal Smears - economics
title Cervical cancer screening and associated treatment costs in France
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T19%3A13%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cervical%20cancer%20screening%20and%20associated%20treatment%20costs%20in%20France&rft.jtitle=Gyn%C3%A9cologie,%20obst%C3%A9trique%20&%20fertilit%C3%A9&rft.au=Bergeron,%20C&rft.date=2006-11&rft.volume=34&rft.issue=11&rft.spage=1036&rft.epage=1042&rft.pages=1036-1042&rft.issn=1297-9589&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E68209912%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68209912&rft_id=info:pmid/17070085&rfr_iscdi=true